| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
EndothelinAmbrisentanEnrasentanBosentanPulmonary hypertensionNicotineSubarachnoid hemorrhageClazosentanEndothelin converting enzymeKidney (Chronic renal failure)Eisenmenger s syndromeNADPH oxidaseBlood vessels (Physiology)| 1 | 1994 | Endothelins. Biochemistry and pathophysiologic actions. | 
| + | - | nl | Anesthesiology 80(4):892-905 (1994) |
| 2 | 2005 | Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. |
| + | - | nl | Heart 91(6):825-31 (2005) |
| 3 | 2006 | Ambrisentan, a non-peptide endothelin receptor antagonist. |
| + | - | nl | Cardiovasc Drug Rev 24(1):63-76 (2006) |
| 4 | 2005 | CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme. |
| + | - | nl | Cardiovasc Drug Rev 23(4):317-30 (2005) |
| 5 | 2003 | Enrasentan, an antagonist of endothelin receptors. | 
| + | - | nl | Cardiovasc Drug Rev 21(1):1-16 (2003) |
| 6 | 2002 | Endothelin antagonism with bosentan: current status and future perspectives. |
| + | - | nl | Cardiovasc Drug Rev 20(1):1-18 (2002) |
| 7 | 2010 | Endothelin receptor antagonists for pulmonary arterial hypertension: an overview. |
| + | - | nl | Cardiovasc Ther 28(5):e65-71 (2010) |
| 8 | 2007 | The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. |
| + | - | nl | Cardiovasc Res 76(1):8-18 (2007) |
| 9 | 2004 | The endothelin system in pulmonary arterial hypertension. |
| + | - | nl | Cardiovasc Res 61(2):227-37 (2004) |
| 10 | 2001 | Endothelin as a natriuretic hormone: the case for a paracrine action mediated by nitric oxide. |
| + | - | nl | Cardiovasc Res 51(3):481-8 (2001) |
| 11 | 1997 | Endothelin: from molecule to man. |
| + | - | nl | Br J Clin Pharmacol 44(1):9-20 (1997) |
| 12 | 2002 | International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. |
| + | - | nl | Pharmacol Rev 54(2):219-26 (2002) |
| 13 | 1996 | Molecular pharmacology and pathophysiological significance of endothelin. |
| + | - | nl | Jpn J Pharmacol 72(4):261-90 (1996) |
| 14 | 1991 | Endothelins. |
| + | - | nl | FASEB J 5(12):2713-20 (1991) |
| 15 | 2006 | Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. |
| + | - | nl | Exp Biol Med (Maywood) 231(6):653-95 (2006) |
| 16 | 2008 | Role of endothelin-1 in clinical hypertension: 20 years on. |
| + | - | nl | Hypertension 52(3):452-9 (2008) |
| 17 | 1991 | Endothelins: a family of regulatory peptides. State-of-the-art lecture. |
| + | - | nl | Hypertension 17(6 Pt 2):856-63 (1991) |
| 18 | 1996 | Endothelin in renal pathophysiology: from experimental to therapeutic application. |
| + | - | nl | Kidney Int 50(6):1827-33 (1996) |
| 19 | 1993 | Renal actions of endothelin. |
| + | - | nl | Kidney Int 44(2):451-63 (1993) |
| 20 | 2010 | Up-regulation of endothelin receptors induced by cigarette smoke--involvement of MAPK in vascular and airway hyper-reactivity. |
| + | - | nl | ScientificWorldJournal 10(-):2157-66 (2010) |
| 21 | 2008 | Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. |
| + | - | nl | Stroke 39(11):3015-21 (2008) |
| 22 | 2008 | Endothelin-converting enzyme inhibitors: their application in cardiovascular diseases. |
| + | - | nl | Rev Port Cardiol 27(3):385-408 (2008) |
| 23 | 2009 | Drug discovery for overcoming chronic kidney disease (CKD): the endothelin ET B receptor/nitric oxide system functions as a protective factor in CKD. |
| + | - | nl | J Pharmacol Sci 109(1):7-13 (2009) |
| 24 | 2008 | The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? |
| + | - | nl | Br J Pharmacol 153(6):1105-19 (2008) |
| 25 | 2011 | Endothelin. |
| + | - | nl | Cell Mol Life Sci 68(2):195-203 (2011) |
| 26 | 2008 | Endothelin--role in vascular disease. |
| + | - | nl | Rheumatology (Oxford) 47 Suppl 5(-):v23-4 (2008) |
| 27 | 2009 | Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: a qualitative systematic review. |
| + | - | nl | Can J Cardiol 25(3):e63-8 (2009) |
| 28 | 2010 | Role of endothelin receptor A and NADPH oxidase in vascular abnormalities. | 
| + | - | nl | Vasc Health Risk Manag 6(-):787-94 (2010) |
